SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Medically accurate illustration of lung cancer. showing presence of cancerous tumor inside the lungs. 3d illustration
Lung Cancer
Summit’s Bispecific Misses Survival Endpoint in Global Phase III Trial but Analysts Remain Optimistic
Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient populations.
May 30, 2025
 · 
3 min read
 · 
Nick Paul Taylor
Contemporary art collage. Businessman putting voting paper into ballot box sticking out from retro computer motinor. Choosing right candidate to run he company. Online voting, election concept
Diversity, equity & inclusion
Merck CEO Calls Diversity ‘Core’ to Operations as Anti-DEI Measure Is Defeated
The National Legal and Policy Center, a right-wing advocacy and watchdog group, had asked the company to revisit its DEI goals in executive pay incentives.
May 30, 2025
 · 
3 min read
 · 
Annalee Armstrong
Astellas' headquarters for the Americas
Collaboration
Astellas Keeps Chinese Collab Train Chugging With $1.5B+ Bet for Claudin ADC
At the heart of the deal is an anti-Claudin18.2 antibody-drug conjugate being developed for solid tumors, including gastric cancer and pancreatic cancer.
May 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Businessman makes employee cuts as part of layoff
Layoffs
After Safety Stumbles, Keros Axes Pulmonary Hypertension Drug, 45% of Staff
Keros will be down to 85 full-time employees after the layoffs and expects to generate annualized savings of $17 million.
May 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Hanging questions.Blue background.
Government
Fake Citations Plague RFK Jr.’s MAHA Report
According to the nonprofit news outlet NOTUS, at least seven studies cited in the Make America Healthy Again report released last week are nonexistent. The White House shrugged off questions about the errors.
May 30, 2025
 · 
2 min read
 · 
Tristan Manalac
vector liver on top of a pedestal on a white background
Gene therapy
Analysts Brush Off Intellia’s Adverse Event but Gene Therapy Safety Concerns Continue
While an adverse event reported in Intellia’s gene therapy trial was a “non-concern” for analysts, it follows a handful of patient deaths in other trials for the modality and sent the company’s stock tumbling in pre-market trading.
May 29, 2025
 · 
3 min read
 · 
Annalee Armstrong
Photo of Manhattan skyline
Job Trends
7 Companies Hiring in New York
Looking for a biopharma job in New York? Check out the BioSpace list of seven companies hiring life sciences professionals like you.
May 29, 2025
 · 
2 min read
 · 
Angela Gabriel
Contemporary art collage of a hand holding scissors. Copy space for ad. Modern design.
Lung cancer
Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings
Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations.
May 29, 2025
 · 
2 min read
 · 
Tristan Manalac
Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.
Company closure
iTeos To Close Down After TIGIT Fail
iTeos expects to absorb nearly $25 million in one-time costs for severance and termination payments. The biotech had 173 full-time employees at the end of 2024.
May 29, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS